J

Japan Tissue Engineering Co Ltd
TSE:7774

Watchlist Manager
Japan Tissue Engineering Co Ltd
TSE:7774
Watchlist
Price: 495 JPY 0.2% Market Closed
Market Cap: 20.1B JPY
Have any thoughts about
Japan Tissue Engineering Co Ltd?
Write Note

Japan Tissue Engineering Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Japan Tissue Engineering Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
J
Japan Tissue Engineering Co Ltd
TSE:7774
Income from Continuing Operations
-ÂĄ81.8m
CAGR 3-Years
42%
CAGR 5-Years
-1%
CAGR 10-Years
21%
GNI Group Ltd
TSE:2160
Income from Continuing Operations
ÂĄ5.4B
CAGR 3-Years
51%
CAGR 5-Years
51%
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Income from Continuing Operations
ÂĄ17.1B
CAGR 3-Years
40%
CAGR 5-Years
46%
CAGR 10-Years
64%
Takara Bio Inc
TSE:4974
Income from Continuing Operations
ÂĄ145m
CAGR 3-Years
-79%
CAGR 5-Years
-49%
CAGR 10-Years
-22%
Pharma Foods International Co Ltd
TSE:2929
Income from Continuing Operations
ÂĄ3.2B
CAGR 3-Years
-6%
CAGR 5-Years
45%
CAGR 10-Years
80%
C
Cuorips Inc
TSE:4894
Income from Continuing Operations
-ÂĄ632.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Japan Tissue Engineering Co Ltd
Glance View

Market Cap
20.1B JPY
Industry
Biotechnology

Japan Tissue Engineering Co., Ltd. engages in the research, development, and manufacture of cultured biological cells and tissues. The company is headquartered in Gamagori-Shi, Aichi-Ken and currently employs 200 full-time employees. The company went IPO on 2007-12-21. The firm operates its business in two segments. The TEP segment is engaged in the research and development of self-cultured epidermis, self-cultured cartilages and self-cultured corneal epithelium for medical institutions. The Research and Development Supports segment is engaged in the development, manufacture and sale of laboratory human cultured tissues based on tissue engineering technology and manufacturing know-how for cosmetic and pharmaceutical product manufacturers.

Intrinsic Value
367.22 JPY
Overvaluation 26%
Intrinsic Value
Price
J

See Also

What is Japan Tissue Engineering Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-81.8m JPY

Based on the financial report for Jun 30, 2024, Japan Tissue Engineering Co Ltd's Income from Continuing Operations amounts to -81.8m JPY.

What is Japan Tissue Engineering Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
21%

Over the last year, the Income from Continuing Operations growth was 82%. The average annual Income from Continuing Operations growth rates for Japan Tissue Engineering Co Ltd have been 42% over the past three years , -1% over the past five years , and 21% over the past ten years .

Back to Top